Wedbush analyst Robert Driscoll reiterated a Buy rating on Tango Therapeutics (TNGX – Research Report) today and set a price target of $18.00. The company’s shares opened today at $3.68.
According to TipRanks, Driscoll is an analyst with an average return of -1.0% and a 33.56% success rate. Driscoll covers the Healthcare sector, focusing on stocks such as Foghorn Therapeutics, Adicet Bio, and Janux Therapeutics Inc.
Tango Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.25.
See the top stocks recommended by analysts >>
TNGX market cap is currently $322.8M and has a P/E ratio of -2.90.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BCTG Acquisition Corp is a blank check company.
Read More on TNGX:
- Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights
- TNGX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting
- Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers
- Tango Therapeutics announces FDA clearance of IND application for TNG260
